Park Place Capital Corp Sells 1,002 Shares of Zoetis Inc. (NYSE:ZTS)

Park Place Capital Corp lowered its position in shares of Zoetis Inc. (NYSE:ZTS) by 27.3% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 2,667 shares of the company’s stock after selling 1,002 shares during the quarter. Park Place Capital Corp’s holdings in Zoetis were worth $451,000 as of its most recent SEC filing.

Other institutional investors have also bought and sold shares of the company. Blue Bell Private Wealth Management LLC boosted its position in Zoetis by 222.5% during the fourth quarter. Blue Bell Private Wealth Management LLC now owns 129 shares of the company’s stock valued at $25,000 after acquiring an additional 89 shares during the last quarter. Independence Bank of Kentucky boosted its position in Zoetis by 371.4% during the fourth quarter. Independence Bank of Kentucky now owns 165 shares of the company’s stock valued at $33,000 after acquiring an additional 130 shares during the last quarter. Private Wealth Management Group LLC bought a new position in shares of Zoetis during the 4th quarter worth about $33,000. Webster Bank N. A. boosted its position in shares of Zoetis by 89.1% during the 1st quarter. Webster Bank N. A. now owns 174 shares of the company’s stock worth $29,000 after purchasing an additional 82 shares in the last quarter. Finally, Ramirez Asset Management Inc. bought a new position in shares of Zoetis during the 3rd quarter worth about $35,000. Institutional investors own 92.80% of the company’s stock.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Thursday, April 18th. The shares were sold at an average price of $151.17, for a total transaction of $139,529.91. Following the completion of the sale, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 0.16% of the stock is currently owned by company insiders.

Wall Street Analyst Weigh In

ZTS has been the topic of a number of research analyst reports. HSBC cut their price objective on shares of Zoetis from $230.00 to $225.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th. Piper Sandler reissued an “overweight” rating and set a $195.00 price objective (down previously from $220.00) on shares of Zoetis in a research report on Tuesday, April 16th. Barclays cut their price objective on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a research report on Tuesday, April 23rd. The Goldman Sachs Group cut their price objective on shares of Zoetis from $223.00 to $196.00 and set a “buy” rating on the stock in a research report on Monday, May 6th. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $195.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, April 30th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $211.75.

Zoetis Trading Down 0.4 %

NYSE:ZTS opened at $172.58 on Tuesday. The company has a debt-to-equity ratio of 1.30, a quick ratio of 1.94 and a current ratio of 3.33. The firm has a market cap of $78.75 billion, a price-to-earnings ratio of 33.25, a price-to-earnings-growth ratio of 2.69 and a beta of 0.86. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $201.92. The firm has a 50-day moving average price of $168.69 and a two-hundred day moving average price of $178.59.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, May 2nd. The company reported $1.38 EPS for the quarter, beating the consensus estimate of $1.34 by $0.04. The firm had revenue of $2.19 billion during the quarter, compared to analyst estimates of $2.14 billion. Zoetis had a net margin of 27.38% and a return on equity of 50.34%. The company’s revenue for the quarter was up 9.5% on a year-over-year basis. During the same quarter last year, the business posted $1.31 EPS. On average, equities analysts expect that Zoetis Inc. will post 5.76 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, September 4th. Stockholders of record on Thursday, July 18th will be paid a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, July 18th. This represents a $1.73 annualized dividend and a dividend yield of 1.00%. Zoetis’s payout ratio is currently 33.33%.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.